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Abstract
Background: Antioxidant molecules, which scavenge free radical species to prevent or delay
oxidative damage of important macromolecules, membrane lipids and lipoproteins, are prevalent
in plasma and other biological fluids. Among them, bilirubin, uric acid and protein thiols are the
major endogenous antioxidants, while vitamins C and E, as well as a number of food-derived
(poly)aromatic substances, belonging to stilbens, flavonoids and phenolic acids, are the main classes
of nutritional antioxidants. Assays for total antioxidant capacity in plasma differ in their type of
oxidation source, target and measurement used to detect the oxidized product.
Methods: In the present work we present an automated assay for the estimation of blood total
antioxidant capacity (TAC assay), based on the crocin bleaching (oxidation) method. This method
was adapted on a modern autoanalyzer, was linear over a wide range of values (0–3 mmol/L), and
performed using an end point measurement.
Results: The TAC method presented a linear correlation with another automated commercial
Total Antioxidant Status (TAS) test. Detection of the interference of different metabolites revealed
a significant participation of TAC from uric acid, bilirubin, albumin, a minor interference from
ascorbic acid, and no interference from hemoglobin. TAC was not modified by two freeze/thawing
cycles, and was stable in samples stored at room temperature for 4 hours. K-EDTA and heparin
were the best anticoagulants, while citrate decreased TAC by 20%. Reference values derived from
samples of normal blood donors was 1.175  0.007 mmol/L (mean  SEM), while a diet rich in
antioxidants more than doubled this value.
Conclusions: The proposed TAC assay, is fully automated, stable and reliable, and could be of
value in the estimation of the AC of plasma. It is further proposed to calculate the antioxidant
capacity of plasma after a subtraction of all interference deriving from endogenous and/or
exogenous metabolites. The antioxidant capacity of plasma thus calculated can be used as a useful
indicator of the antioxidant value of foods and beverages in the daily diet.
Published: 28 August 2002
BMC Clinical Pathology 2002, 2:3
Received: 9 May 2002
Accepted: 28 August 2002
This article is available from: http://www.biomedcentral.com/1472-6890/2/3
© 2002 Kampa et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted 
in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
Page 2 of 16
(page number not for citation purposes)
Background
Evidence from biochemical and animal models suggests
that nutritional antioxidants protect against the develop-
ment of chronic diseases, including coronary heart dis-
ease, atherosclerosis and certain forms of cancers.
However, this hypothesis is not clearly corroborated by
intervention studies in human subjects, due, in part, to in-
adequacies in current analytical methodologies. Indeed,
although in vitro assays may give useful information on
the attributes required by a compound to act as an antioxi-
dant, results have limited nutritional relevance [1], since
plasma and other biological fluids abound in antioxidant
molecules, which scavenge free radical species thus reduc-
ing oxidative damage of either macromolecules, mem-
brane lipids or lipoproteins. Bilirubin, uric acid and
protein thiols are major endogenous antioxidants, while
vitamins C and E, as well as a number of food-derived
(poly)aromatic substances, belonging to stilbenes, flavo-
noids and phenolic acids are the main classes of nutrition-
al antioxidants [2–5].
Assays for total antioxidant capacity in plasma differ in
their type of oxidation source, target and measurement
used to detect the oxidized product. These assays give a
wide range of results, should never be used in isolation,
and results should be interpreted with caution [1]. To
counteract these limitations, several methods have been
proposed for determination of total plasma antioxidant
capacity (TAC). They can be divided in two main classes:
Either distinct antioxidant components are assayed (ex.
Vitamin E, ascorbic acid, etc), or the total antioxidant po-
tency is estimated by the combined reducing activities of
a given body fluid (especially plasma). A number of meth-
ods have been developed for this later estimation, given
the considerable interest in antioxidants as bioactive com-
ponents of food and as nutritional agents with a role in
the maintenance of health and in disease prevention [6].
Indeed, there are situations in which knowledge of the in-
dividual levels of specific antioxidant components might
be less useful than the total antioxidant potency of the
medium concerned. Such situations might be in the un-
derstanding of structure-activity relationships of pure
antioxidant compounds, in the determination of the anti-
oxidant contributions of specific dietary components and
how this relates to the antioxidant composition and activ-
ities of the individual constituents, and in the study of de-
creases in plasma antioxidant activity in individuals under
oxidative stress in specific disease states [7]. The total anti-
oxidant activity of plasma has been assayed by a number
of different methods including oxygen consumption dur-
ing lipid peroxidation [8], luminol-enhanced chemilumi-
nescence [9], measurement of R-phycoerythrin bleaching
[ORAC method [10–12]], sensitivity of erythrocytes to
hemolysis [13], ferric reducing activity [14], lipid perox-
ides generation [15,16], and finally carotenoid (crocin)
bleaching [17]. This latter method has been used in food
chemistry for assaying the antioxidant capability of com-
plex food mixtures. A recent development of this method,
based on serial dilutions of human plasma, has been re-
cently reported, allowing the determination of the plasma
antioxidant activity in humans [18]. The present work
builds on these data, proposes additional modifications
and attempts to automate it, in order to meet the require-






carboxylic acid (Trolox C) were purchased from Sigma-
Aldrich (Milwaukee, WI). ABAP was dissolved just before
use with a 10 mM Phosphate buffer (pH 7.4) at concen-
trations varying from 4–10 mg/ml. The usual concentra-
tion used was 5 mg/ml. Saffron (Greek red saffron of the
COUPE class) was purchased from the Association of Saf-
fron producers (Krokos, Kozani, GR). All other chemicals
and biochemicals were from Sigma (St Louis, MO), or
Merck (Darmstad, De). Crocin was isolated from saffron
by water/methanol extraction after repeated extraction
with ethyl-ether, as described previously [18]. After extrac-
tion, crocin was tested for purity (absorbance peak at 440
and a shoulder at 464), diluted in 30% methanol in water,
diluted fivefold with phosphate buffer (10 mM, pH 7.4),
and the concentration of crocin was adjusted to 20 M
with buffer, using the molecular absorbance coefficient of
crocin 443 = 89000 M-1cm-1[19]. Aliquots of crocin, pro-
tected from light, weres to redat -20C, until use. Caffeic
(97%), ferulic (99%) and protocatechuic (99%) acids
were purchased from Sigma-Aldrich Chemical Co. (Mil-
waukee, WI). Sinapic (98%), syringic (98%), 3,4-dihy-
droxyphenylacetic acids and epigalocatechin were from
Sigma Chemical Co. (St. Loui, MO), while quercetine was
a kind gift from Prof. J. Vercauteren (University of Bor-
deaux I, France).
Instruments
Spectrophotometric determinations were performed with
a Kontron Uvicon 860 Spectrophotometer (Paris, France).
An Athos 2001 microplate reader (Vienna, Austria), with
a filter at 450 nm was used for initial microplate assay.
Later, the automated microplate apparatus Triturus (Gri-
fols, Barcelona, Spain), equipped with a pipettor, an incu-
bator and a reader station, connected and driven from a
PC station was used. Finally, the Olympus AU 400 auto-
analyzer was used for the automated assay.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Figure 1
Antioxidant capacity of a number of phenolic acids (A) and polyphenols (B) on the TAC assay. The indicated concentrations of differ-
ent phenolic acids (A) and purified polyphenols (B) were assayed for their inhibitory effect of crocin oxidation, over the range
0–10 g/ml for phenolic acids and 10-7–10-5 M for polyphenols. A Trolox standard curve is presented for comparison.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Methods
Colorimetric method for the determination of the TAC of human 
plasma
The method for manual TAC plasma determination was
previously described by Lusignoli et al [18]. In brief, in
each well of the microplate 100 l of crocin and 50 l of
the plasma sample, diluted in phosphate buffer were pi-
petted. The reaction was initiated with the addition of 100
l of prewarmed (37C) ABAP (5 mg/ml), and crocin
bleaching was made by incubating the plate at a humidi-
fied thermostated oven at 37C, for 60–75 min. Blanks
consisted of crocin, plasma samples, and phosphate buff-
er (100, 50 and 100 l respectively) were run in parallel.
The absorbance was measured at 450 nm. The specific ab-
sorbance was then calculated by subtracting the corre-
sponding blank value, and the antioxidant activity was
calculated as the ratio: 100  (Abs0-Abssample)/Abs0, in
which Abs0 was the absorbance in the absence of antioxi-
dants, and Abssample was the absorbance in the presence
of sample. A standard curve of the water-soluble synthetic
antioxidant Trolox, prepared prior to use, ranging from 0–
10 g.ml was equally assayed under the same conditions.
Automation of TAC method
The above method was adapted to the Triturus microplate
automate, using exactly the above-described protocol. The
adaptation of the method to the Olympus autoanalyzer
was based on the measurement of the inhibition that is
caused by total antioxidants on the bleaching of crocin
from ABAP. The procedure was as follows: A concentra-
tion of crocin isolated from saffron as previously de-
scribed [18], was adjusted at 25 M with 10 mM
phosphate buffer, pH 7.4 (A) and mixed with an inert fill-
er at a final concentration of 7.5% (w/w). Three ml of the
above solution were dispensed into glass vials, lyophi-
lized on BOC Edwards Calumatic Lyoflex 0.8 lyophilizer
and sealed under vacuum after the end of lyophilization.
Each vial was reconstituted with 7.5 ml of buffer A prior
to use. The reconstituted solution was R1 of the final assay
while R2 was a ready-to-use liquid reagent containing 50
mg/ml ABAP in buffer A. For the automated procedure a
blank reagent was run together with the above-described
reagent. The blank reagent was consisted of buffer A as
R1blank and 50 mg/ml ABAP in buffer A as R2blank.
The assay was performed at 37C in the following steps:
Two l of sample, calibrator or control were mixed with
250 l of crocin reagent (R1) and this mixture was incu-
bated for 160 s. Thereafter, 250 l ABAP reagent R2 were
added and the decrease in absorbance at 450 nm was
measured 256 s later. An analogous reaction was per-
formed for the sample blank assay using blank reagents,
as mentioned above. The difference between the two sig-
nals for the reaction and the reagent blank reaction (the
reaction using deionised water as sample) was used to es-
tablish the standard curve and to calculate values of con-
trols and serum samples. The result was always negative,
indicating an inhibition in the development of color com-
pared to the reaction in the absence of antioxidants i.e.,
sample.
All biochemical parameters were assayed on an Olympus
AU400 autoanalyzer. Reagent for the measurement of
Uric acid was from OLYMPUS Diagnostica GmbH, Lism-
mehan, Ireland and the reagent for TAS activity was from
RANDOX Laboratories Ltd, United Kingdom. All other re-
agents were from Sigma (St Louis, MO) except where indi-
cated.
For the interference studies we used the following materi-
als: Hemoglobin: Erythrocytes were washed with physio-
logical saline, and a hemoglobin solution was prepared
through hemolysis, by adding distilled water. Bilirubin:
Crystallized bilirubin was dissolved into a very small
quantity of weak alkaline (0.1 N NaOH) solution. Conju-
gated Bilirubin: Conjugated bilirubin (CalbioChem, La
Jolla, CA) was dissolved into a very small quantity of wa-
ter. Turbidity: Intralipid 10% (Pharmacia (Hellas) SA,
Athens, Greece) was used with no further treatment.
Ascorbate: (Merck, Darmstadt, Germany) was dissolved
into distilled water. Bovine serum albumin (protease
free): Serological Products (IL).
All biochemical parameters were assayed on an Olympus
AU 400 autoanalyzer, with Olympus reagents provided
from Medicon Hellas (Gerakas, Greece). (Albumin
OSR6102, total bilirubin OSR6112, iron OSR6123 uric
acid OSR6136).
Blood samples
Forty healthy blood donors, aged 21–52 years (28 males,
and 12 females) from the region of Heraklion, Crete, were
used for the determination of the reference interval of the
TAC assay. They were on a normal diet, while we had little
information of their nutritional and smoking habits. In
addition, one hundred samples from the hematology lab-
oratory of the Heraklion University Hospital, with no in-
dication of the underlying pathology were further used for
the correlation of TAC assay with the uric acid, bilirubin,
iron and protein concentrations. Finally, 17 nuns, from
an orthodox monastery in the region of Heraklion were
assayed, after a 40 days ritual fasting before Easter. This
fasting consisted in the abolishment of all animal food
from their diet.
Blood samples were usually collected on K3-EDTA, and
immediately centrifuged in a refrigerated centrifuge. They
were aliquoted, and stored at -80C until use.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Figure 2
Effect of freeze/thawing cycles on the plasma concentration of TAC. Ten different plasmas, collected on K-EDTA were assayed for
TAC following the manual method described in the Material and Methods section. In A, different plasma volumes were assayed
after 1–4 freezing cycles. In B, the calculated TAC concentration per l of plasma was reported over the number of freezing
cycles. Mean  SEM of 10 different plasma samples, from normal individuals.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Statistical analysis
The statistical analysis of the results was performed using
parametric methods, with the aid of the Origin v 5.0 (Mi-
crocal Software, Northampton, MA) and the Systat v 10.0
(SPSS, Chicago, IL) microcomputer programs.
Results
Validation of the assay
Reagents and antioxidants
As indicated in the original paper for the assay [18], crocin
spectra in the oxidized and the reduced form present an
absorption maximum at 440 nm. This was also verified in
the present work (not shown). In addition, different con-
centrations of ABAP, in the presence of 5 M crocin, were
assayed. Concentrations of 4–5 mg/ml produced a very
sensitive curve, while the sensitivity was lost at ABAP con-
centrations >6 mg/ml. In view of these results, an ABAP
concentration of 5 mg/ml was chosen. On the other hand,
an optimum crocin concentration of 5 M was chosen, af-
ter a series of different dilutions, ranging from 2 to 20 M,
concentrations which, after 60–75 min incubations gener-
ated similar curves as in the original publication [18].
A series of antioxidant phenolic acids, found in a number
of foods was tested for inhibition of crocin, in the assay
generated by the use of the above concentrations of ABAP
and crocin. The results are presented in Figure 1A. As
shown, all phenolic acids produced a dose-dependent in-
hibition of crocin oxidation. Caffeic acid was the most po-
tent inhibitor of crocin oxidation, followed by sinapic and
ferulic acid. Protocatechuic, siringic and dihydrophenyl
acetic acids exhibited the lower antioxidant activity, a re-
sult reported previously in other in vitro systems [20]. Fig-
ure 1B on the other hand, presents the crocin inhibition
in the presence of two polyphenols: quercetine and epi-
gallocatechin. As shown, both polyphenols produce a
dose-dependent inhibition of crocin oxidation, indicating
that the assay could be used for the determination of anti-
oxidants in a number of natural products, such as wine,
olive oil or tea.
Plasma
In the original assay, serial dilutions of plasma were tested
for their inhibitory activity on crocin oxidation by ABAP,
the antioxidant capacity of the plasma was calculated by
the sigmoidal fitting of the resulting curve, and the calcu-
lation of the IC50, reported finally to the Trolox inhibitory
curve. In the present work, the inhibitory activity of hu-
man plasma on crocin oxidation was directly reported to
the Trolox curve, and the equivalent Trolox activity was di-
rectly calculated. Long incubation times (60–75 min)
were used, in order to minimize the lag time of antioxi-
dant activity reported in the initial kinetic assay of crocin
bleaching [17]. For this purpose, we have linearized the
Trolox curve through a Log/Normal plot, calculated the
equation of the straight line, and reported directly the ob-
tained inhibitions of plasma to the equation. The coeffi-
cient of correlation (r2) of the Trolox linearized assay was
>0.996. We have assayed 10 different plasma samples,
collected on K3-EDTA, for their antioxidant activity, im-
mediately after collection and after 1–4 freeze-thawing cy-
cles. After one freeze/thawing cycle results were identical
(see also Table 1). The same result was obtained from one
to three freezing cycles, as shown in Figure 2A, for plasma
volumes from 2 to 5 l. In contrast, a complete annihila-
tion of the plasma antioxidant capacity was observed after
a fourth freezing cycle. The calculated IC50s, through sig-
moidal fitting of the data presented in Figure 2A gave val-
ues of 3.36  0.44, and 3.06  0.39 l of plasma,
corresponding to 1.23  0.09 g of Trolox for 1 or two
freezing cycles, not different from those reported in the
original publication (2.70  0.49  l of plasma, corre-
sponding to 1.38 Trolox equivalents). In contrast, after
three freezing cycles, IC50 was significantly reduced to
1.87  0.21 l of plasma, and annihilated after four freez-
ing cycles. It was therefore concluded that plasma must be
Table 1: Effect of different anticoagulants and blood preservation on the TAC assay. Results are presented as mean  SEM of ten differ-
ent assays, and expressed as mmol/L.
StorageConditions Immediate plasma separa-
tion
Storage at room tempera-
ture for 4 hours
Storage at 4C for 4 hours
Anticoagulant
None (serum) 1.09  0.04 1.10  0.03 1.09  0.03
K-EDTA 1.03  0.05 1.02  0.03 1.01  0.04
Citrate 0.82  0.04 0.81  0.03 0.83  0.03
Heparin 1.04  0.05 1.08  0.04 1.04  0.04BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
Page 7 of 16
(page number not for citation purposes)
used either immediately, or after a maximum of two
freeze/thawing cycles.
Figure 2B presents the calculated TAC expressed as Trolox
equivalent per l of plasma. As shown, minor changes in
the calculated TAC/l were found when 3.3–5 l of plas-
ma were used in the assay and the number of freeze cycles
was <3. In contrast, a linear decrease of the calculated
TAC/l was found when 2 l of plasma were used. As ex-
pected from the data presented in Figure 2A, a dramatic
decrease of the TAC was observed after four freezing cy-
cles. The TAC per unit of volume calculated and presented
in Figure 2B (0.37  0.07 g of Trolox equivalent) is not
significantly different from the one calculated from the
IC50s presented in Figure 2A (0.38  0.04). In view of this
result, we have therefore concluded that we could use a
plasma volume between 3 and 5 l, and calculate directly
the TAC from the linearized Trolox curve. This method
was further used in the following experiments.
Validation of automated TAC assay
Based on the above results, an automated assay has been
developed, as described under Material and Methods. This
assay was further validated in various experimental condi-
tions:
TAC of human plasma
Linearity
As presented above, a major disadvantage of the manual
method is non-linear Trolox standard curves. Therefore, a
Log/Linear plot is needed, in order to calculate the results.
It order to simplify the assay, and to make it suitable for
an end-point determination on different auto-analyzers,
we have modified the assay volumes and reagents, as de-
scribed in the Material and Methods section. The obtained
curve, assayed on an auto-analyzer was linear, over the
range of 0–3 mmol/L (Figure 3), a concentration includ-
ing the majority of the obtained values (see later results).
Figure 3
Linearity of the automated TAC assay A standard curve of 0–3 mmol/L of Trolox was assayed on an Olympus AU400 auto-ana-
lyzer. The results of the inhibition of crocin oxidation are presented as the absorbance at 450 nm. A linear fit of the data is also
presented.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Correlation between TAC and TEAC
The only fully automated method of plasma antioxidant
activity in the market is the Total Antioxidant Status assay
by Randox (Antrtim, UK), based on the TEAC method, in-
itially described by Miller and Rice-Evans [21–23]. We
have performed therefore both assays on a number of 44
human plasma samples. The results are presented in Fig-
ure 4. As shown, with the exception of four outliers
(marked as diamonds) a very good linear correlation (r =
0.8478, p < 0.0001) was found between the two assays.
Nevertheless, the intercept of the linear fit is 0.51 mmol/
L, indicating that at low concentrations TAC results tend
to be lower than the TAS assays, while the coefficient of
the linear fit is 1.4, suggesting that these two assays based
on the oxidation of different substances, might measure a
slightly different number of circulating antioxidants.
Reference values
Based on a number of 44 human blood donors (freezed
plasmas), the reference values of TAC were estimated to be
1.175  0.007 mmol/L, similar to the RAS (Randox) assay
of the total antioxidant status, which, estimated on the
same samples was found to be 1.209  0.005 mmol/L.
Dilutions
A concentration of 4.0 mmol/L of Trolox in normal saline
was diluted serially, and assayed 10 times. In addition, the
same dilution of Trolox was diluted in a plasma sample
(target value 0.86 mmol/L) 1/1 (v/v), and assayed 10
times, performing serial dilutions in normal saline. The
results, presented in Figure 5, show that the TAC assay
show a linear relation of values in log/log coordinates, in-
dicating that dilution of plasmas do not introduce an in-
terference in the TAC assay. In addition, the target value of
Figure 4
Correlation between TAC and TEAC Correlation of the TAC assay and the Randox Total Antioxidant Status assay (TAS), based on
the TEAC method, initially described by Miller and Rice-Evans [21–23]. Both assays were performed serially on the same auto-
analyzer on 44 human plasma samples. Diamonds show four outliers.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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plasma, in which a reference concentration of Trolox was
introduced (2.53 mmol/L) was not significantly different
from the one assayed by the TAC assay 2.705  0.170
mmol/L).
Effect of anticoagulants and storage
A number of anticoagulants have been tested for blood
collection, under different conditions. The obtained re-
sults are presented in Table 1. As shown, heparin and K3-
EDTA gave similar results, in all experimental conditions.
In contrast, citrates decreased the TAC by about 20%. Se-
rum values, in the same samples, showed a 5% more ele-
vated results.
Effect of freezing
A number of ten different plasma samples from normal
individuals, collected on K-EDTA, were assayed after a
number of 1–5 freeze/thawing cycles. As shown in Table
2, one to three freezing cycles did not produce any differ-
ence in plasma TAC. In contrast, and inversely with the re-
sults of the manual assay, a progressive increase of TAC
values is found after 3 repeated freezing cycles. A possible
explanation for the discrepancy of results between the
manual and the automated method might be the fact that
automated method, using smaller volumes of plasma,
might be more sensitive to repeated freeze thawing, or al-
ternatively, to plasma modifications produced by repeat-
ed freezing. Nevertheless, the fact that the automated
method produces stable results during three freeze thaw-
ing cycles, makes it a robust technique for use in clinical
practice.
Inter- and Intra-assay coefficient of variation
A number of ten different plasma samples, were assayed
10 times in the same run, after one freeze/thawing cycle,
and in consecutive days, on a new aliquot, for the deter-
mination of intra- and inter-assay coefficient of variation.
A 2.4% intra-assay CV and a 3.2% inter-assay CV were
found.
Figure 5
Effect of dilution on the TAC assayBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Table 2: Effect of repeated freezing cycles on TAC values
Anti-coagulant Number of freeze/thawing cycles
12345
K3-EDTA 1.05  0.02 1.00  0.02 1.05  0.03 1.13  0.03 1.22  0.04
Heparin 1.05  0.03 0.95  0.02 1.00  0.03 1.24  0.04 1.32  0.05
Ten different plasma samples from normal individuals, collected on K3-EDTA or heparin, were assayed after a number of 1–5 freeze/thawing cycles, 
by the automated TAC assay. Values are presented as the mean  SEM. The target value of non-freezed plasma, collected in a K3-EDTA tube was 
given in Table 1
Figure 6
Correlation of TAC and Randox TAS assays with uric acid concentration of human plasmas. The assay was performed on 44 human
plasma samples, serially using the two assays, on the same autoanalyzer (Olympus AU400). Squares represent TAS results,
while diamonds represent TAC results. The straight lines and the correlation equations are also shown.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Effect of endogenous substances
As indicated in the Introduction, a number of investiga-
tors have proposed that uric acid, ascorbate or plasma
proteins could interfere with the measurement of TAC, or
they may represent the major component of TAC [2–5]. In
addition, as the measurement of absorbance of crocin
bleaching is performed at 450 nm, bilirubin could inter-
fere with the assay [18]. We have therefore tested these
contributions in the automated TAC assay.
Uric Acid
Figure 6 shows the correlation of TAC and TAS assays on
uric acid concentration of human plasmas. As shown,
straight lines crossed the ordinate axes at 0.57 and 0.82
mmol/L of TAC and TAS respectively. This result indicates
that about 49% of the measured TAC activity is due to uric
acid, significantly lower than the contribution of TAS on
uric acid, calculated to 68%. The slope of the straight line
obtained between TAC and uric acid indicates that 0.11
mmol/L of TAC correspond to 1 mg/dl of uric acid.
Other endogenous substances
In order to evaluate the interference of a number of other
endogenous substances, we have performed the introduc-
tion in given samples of varying concentrations of ascor-
bate, lipids, bilirubin (total and conjugated) and
hemoglobin. Our results (Figure 7), presented as an in-
creased TAC over the sample concentration, show that
ascorbate shows a statistically significant relationship of
TAC values (r = 0.86, p < 0.0001). Analysis of the results
indicates that there is a slope of 0.07 mmol/L of TAC per
mg/dl of ascorbate. Bilirubin represents a possible inter-
ference to the TAC assay [18], due to its antioxidant capac-
ity and to the fact that it presents an absorption maximum
Figure 7
Effect of different analytes on the TAC assayBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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at 450 nm, a wavelength used in the TAC assay. Indeed, as
shown in Figure 7, a significant correlation could be ob-
served with increasing bilirubin concentrations varying
from 0–20 mg/dl (r = 0.98, p < 0.0001). Analysis of the
linear fit indicated an increase of 0.14 mmol/L of TAC per
mg/dl of bilirubin. Taking into account that normal bi-
lirubin values are lower than 1 mg/dl, it was concluded
that about 12% of TAC might be attributed to this analyte.
Nevertheless, a higher interference might be expected in
icteric patients. The same linear correlation is also found
with the water-soluble conjugated bilirubin concentra-
tion. In this case, the interference was 0.11 mmol/L of
TAC per mg/dl of conjugated bilirubin. In contrast, hemo-
globin did not show any significant relationship in the
TAC assay. Albumin is one of the oxidant scavenger sys-
tems in plasma. Nevertheless, as shown in Figure 7, a mi-
nor interference of albumin (ranging from 0 to 20 mg/dl)
was found on the TAC assay. A significant correlation (r =
0.8992, p < 0.0004) was observed, while an interference
of 0.01 mmol/L of TAC was observed per mg albumin/dl.
Finally, total lipids show a strong correlation with TAC (r=
0.99, p < 0.0001) with an increase in TAC of 0.18 per 100
mg/dl of lipids, indicating a participation of 30% in the
TAC assay.
Figure 8
Effect of diet on the TAC values in human plasma. TAC assay of 17 samples taken from nuns, from a local monastery, after 40 days
of ritual fasting. Their diet, during this period, was exempted of any animal food, and rich in fruits, vegetables, and extra-virgin
olive oil, and compared the obtained results with 12 normal blood donors. Each dot presents an individual. Mean values  SEM
are also shownBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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Summarizing therefore the different contributions found,
we have concluded that about 85% of TAC, in normal
subjects, is due to endogenous antioxidants, and only
about 15%, under normal circumstances is due to exoge-
nously (dietary provided) antioxidant substances.
Effect of diet
The above conclusion indicates that exogenously provid-
ed antioxidants might modify the TAC of human plasma.
In order to investigate this possibility, we have measured
the TAC of 17 samples taken from nuns, from a local
monastery, after 40 days of ritual fasting. Their diet, dur-
ing this period, was exempted of any animal food, and
was rich in fruits, vegetables, and extra-virgin olive oil. The
results of TAC assay are presented in Figure 8. As shown,
the distribution of TAC in the nuns' group is broader, and
the mean value higher than in samples from normal indi-
viduals (mean values  SEM 2.48  0.10 as compared to
1.20  0.01 mmol/L, t-value 12.8, p < 0.0001). This high
increase of TAC was attributed to the fasting diet followed
by this group, as all other analyte measurements were
comparable between the two groups.
Discussion
Reactive oxygen species (ROS) as well as reactive nitrogen
species (RNS) are produced as a consequence of normal
aerobic metabolism in animal species [24–26]. These
"free radicals" are removed and/or inactivated in vivo by
a battery of antioxidants [4,24–27]. A biological antioxi-
dant is defined as a substance, which, at low concentra-
tions compared to that of the oxidisable substrate,
significantly delays or prevents this oxidation [6,27,28].
Individual members of the antioxidant defense team are
employed to prevent the generation of free ROS and RNS,
to destroy potential antioxidants and to scavenge ROS
and RNS. However, the relative sufficiency of the organ-
ism antioxidant defenses is critical in the development of
oxidative stress in patients affected by a number of diseas-
es, including HIV infections [29,30], neurodegeneration
[31], diabetes [3,32–34], angina [35–38], certain forms of
cancer [39–47], and probably ageing [48–50]. These dis-
eases are characterized by an overproduction of free radi-
cals, i.e. when the antioxidant defense of an organism is
overwhelmed or are established when a deficit of defenses
of the organism against oxidation occurs.
The primary defense against oxidative stress in extracellu-
lar fluids results from a number of low molecular weight
antioxidant molecules either water – (ex. ascorbic acid) or
lipid-soluble (ex. Vitamin E). These antioxidants can also
be generated during normal metabolism (ex. uric acid, bi-
lirubin, albumin, thiols) or introduced in the body by the
consumption of dietary products rich in antioxidants (ol-
ive oil, fruits and vegetables, tea, wine, etc) [6]. The sum
of endogenous and food-derived antioxidants represents
the total antioxidant activity of the extracellular fluid. In
addition, the levels of these antioxidants are suitable not
only as a protection against oxidation, but could also re-
flect their consumption during acute oxidative stress
states. The cooperation among different antioxidants pro-
vides a greater protection against attack by reactive oxygen
or nitrogen radicals, than any single compound alone.
Thus, the overall antioxidant capacity may give more rele-
vant biological information compared to that obtained by
the measurement of individual parameters, as it considers
the cumulative effect of all antioxidants present in plasma
and body fluids [51]. A theory has recently be proposed,
taking into account the redox potentials of exogenous and
endogenous antioxidants, and the construction of a
chained reaction, in which a given antioxidant, after oxi-
dation is regenerated through a number of reactions in-
volving a number of other, more potent antioxidants.
Through this cascade, interactions among the lipid and
the aqueous phases could be established [52].
A great variety of methods have been proposed for the as-
say of total antioxidant activity or capacity of serum or
plasma [reviewed extensively and critically in [6,51]]. In
these reviews a clear distinction among antioxidant activi-
ty and capacity is made: Antioxidant activity corresponds to
the rate constant of a single antioxidant against a given
free radical. Antioxidant capacity, on the other hand, is the
measure of moles of a given free radical scavenged by a
test solution, independently of the capacity of any one
antioxidant present in the mixture [51]. Therefore, for
plasma, being a heterogeneous solution of diverse anti-
oxidants, the antioxidant status is better reflected by anti-
oxidant capacity rather than activity. This capacity is a
combination of all the redox chain antioxidants, includ-
ing different analytes such as thiol bearing proteins, and
uric acid. Therefore, the plasma antioxidant capacity is
rather a concept than a simple analytical determination.
Indeed, an increase of the antioxidant capacity of plasma
indicates absorption of antioxidants and an improved in
vivo antioxidant status [53], or an adaptation mechanism
to an increased oxidative stress. Nevertheless, due to the
participation of diverse metabolites (see Figures 6 and 7)
to the antioxidant capacity of human plasma, its increase
may not be necessarily a desirable condition. Indeed, in
some cases, such as renal failure (uric acid), icteric status
(bilirubin), hepatic damage (hypoalbuminemia) the var-
iation of several metabolites falsely modifies the plasma
antioxidant capacity, a situation returning to normal val-
ues after correction of the underlying disease [54].
As derived from the definition of antioxidant capacity,
and the heterogeneity of antioxidant substances in human
plasma, all methods used for its determination are by def-
inition indirect [6]. The crocin bleaching method, used in
the present paper, initially described by Tubaro et al [17],BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/3
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and Lusignoli et al [18] uses crocin oxidation by peroxyl
radicals produced by ABAP. By comparing the inhibition
of bleaching (oxidation) of crocin by plasma, to an artifi-
cial antioxidant (Trolox C), either kinetically [17], or at
end point [18], a standard antioxidant capacity of plasma
can be derived, expressed as Trolox equivalent. As dis-
cussed by Prior and Cao [6], a serious problem of the croc-
in method is the lag time phase, when lipids and proteins
act as antioxidants, a result not encountered in the modi-
fication proposed here (Figure 7), at analyte concentra-
tions exceeding by far the reference values in human
plasma. In addition, concerning ascorbic acid (that the
previous kinetic method provides values exceeding all
other reported, 7.7 Trolox equivalents) was not a problem
in the current assay. Indeed, ascorbic acid accounted (on
a molar basis) only for 1.22 Trolox equivalents. Com-
pared to another commercialized antioxidant capacity de-
termination (Total Antioxidant Status by Randox) (see
Figure 4), a significant linear correlation was observed,
while TAC assay tends to assay lower AC by 0.5 mmol/L,
expressed as Trolox equivalents. The TAS assay is based on
the TEAC (Trolox Equivalent Antioxidant Capacity) meth-
od, reported by Miller and Rice-Evans [21–23]. It is based
on the inhibition by antioxidants of the absorbance of the
radical cation of 2,2'-azinobis-(3-ethylbenzothiazoline-6-
sulfonate) (ABTS) formed by the interaction of ABTS with
ferrylmyoglobin radical species. This, also indirect, meth-
od gave similar reference values as the TAC assay, on 44
healthy blood donors (TAS: 1.209  0.005 mmol/L; TAC:
1.175  0.007 mmol/L of Trolox equivalents), measured
serially on the same autoanalyzer.
As discussed elegantly by Prior et al [6], different metabo-
lites interfere with all indirect antioxidant capacity meth-
ods. These endogenous analytes include uric acid,
ascorbate, albumin, bilirubin and lipoproteins. During
the validation of the TAC assay we performed analysis of
the above metabolites on the antioxidant capacity. We
have found that uric acid, bilirubin, ascorbate and lipo-
proteins accounted for 0.11 mmol/mg, 0.14 mmol/mg,
0.07 mmol/mg, and 0.18 mmol/100 mg respectively. Tak-
ing into account the normal concentrations of these ana-
lytes, it was concluded that about 1 mmol/L (i.e. about
85% of the TAC) is due to endogenous analytes, and only
15% of the observed TAC might be due to exogenously
provided antioxidants. Of course, as our reference subjects
were blood donors, we could not have precise evaluation
of their dietary and smoking habits. Indeed, it is well es-
tablished that smoking habits reduce the TAC of human
plasma, a reduction which is reversed after stopping
smoking [51]. Non-smoking nuns, following a diet rich in
antioxidant substances, increase dramatically their TAC of
plasma, demonstrating the importance of dietary antioxi-
dants (Figure 8).
Conclusions
As discussed above, the AC of plasma might be considered
as a concept rather than a pure analytical determination.
Taking into consideration the participation of major ana-
lytes in the bleaching of crocin, we propose the measure-
ment of TAC in relation to these metabolites, in order to
estimate the contribution of exogenous substances to the
total antioxidant capacity. In this way, the possible inter-
ference of endogenous and exogenous antioxidants can be
evaluated and tested in diverse physiological and patho-
logical situations. The TAC assay, fully automated, stable
and reliable could, in such a way be of value in the estima-
tion of the AC of plasma, and the role of different kind of
foods and beverages, with presumed or definite role in hu-
man health, could be evaluated.
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